May 08, 2026 09:01 ET | Source: Royal Philips May 8, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2026, including: Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “On behalf of the Supervisory Board […]
May 07, 2026 02:14 ET | Source: Angelini Pharma; Catalyst Pharmaceuticals ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with
May 06, 2026 12:04 ET | Source: CARBOGEN AMCIS INNOVATIONS AG BUBENDORF, Switzerland, May 06, 2026 (GLOBE NEWSWIRE) — CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announces its Shanghai facility has successfully completed an unannounced Good Manufacturing Practice (GMP) inspection by China’s National Medical Products Administration (NMPA), with no observations.
May 06, 2026 01:00 ET | Source: Royal Philips May 6, 2026 Q1 2026 Group performance Roy Jakobs, CEO of Royal Philips:“We delivered a good start to 2026, with strong order intake growth at 6%, comparable sales growth of 4% and margin expansion of 40 basis points, reflecting disciplined execution against our plan in an uncertain macro-environment.
May 05, 2026 13:00 ET | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026. Demonstrating a long-term commitment to chronic wound management,
May 05, 2026 09:03 ET | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., May 05, 2026 (GLOBE NEWSWIRE) — SK pharmteco announced today that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). This approval confirms that SK pharmteco’s sustainability roadmap aligns with the strict 1.5°C pathway required to fight global climate
May 05, 2026 06:03 ET | Source: Ingredion Incorporated WESTCHESTER, Ill., May 05, 2026 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food and beverage manufacturing industry, today reported its first quarter 2026 results. “While we expected a challenging first quarter after last year’s strong first quarter, results were
May 04, 2026 16:30 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva’s EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May
May 04, 2026 08:00 ET | Source: Dr. Falk Pharma FREIBURG, Germany and ROSCREA, Ireland – May 4, 2026 – Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized
April 30, 2026 15:07 ET | Source: EnGeneIC SYDNEY, May 01, 2026 (GLOBE NEWSWIRE) — EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. The trial
Appointment signals next phase of expansion for HIFU-based prostate care as demand grows for non-invasive, function-preserving treatment options April 30, 2026 09:03 ET | Source: Sonablate CHARLOTTE, N.C., April 30, 2026 (GLOBE NEWSWIRE) — Sonablate, a medical technology company focused on non-invasive prostate cancer treatment using high-intensity focused ultrasound (HIFU), today announced the appointment of Brad Saar, former president
April 29, 2026 06:30 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (“Emalex”) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase
April 29, 2026 06:00 ET | Source: Boehringer Ingelheim Limited INGELHEIM, Germany, and SAN FRANCISCO, US – Boehringer Ingelheim, a global leader in animal health, and Eko Health, a leader in AI-powered cardiac and pulmonary disease detection, announced the launch of an innovative solution to detect, visualize, and grade heart murmurs in dogs. Eko Vet+TM | CANINEBEAT® AI aims to
April 29, 2026 02:49 ET | Source: Enlitic LOVELAND, Colo., April 29, 2026 (GLOBE NEWSWIRE) — Enlitic today announced the completion of its integration with Sectra, enabling Enlitic to support Sectra customers directly with its Ensight platform. The integration marks an important step in expanding access to Enlitic’s imaging data capabilities for healthcare organizations using Sectra. With
April 28, 2026 02:00 ET | Source: Boehringer Ingelheim Limited Ingelheim, Germany. Boehringer Ingelheim today announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoints using both the efficacy and treatment-regimen estimands.*† Adults living with obesity or overweight, without type 2 diabetes, who were treated with survodutide experienced sustained weight
